A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.